NextPharma (PRIVATE.NEXTPHARMA)

Overall impact
B (72)

Commentary

NextPharma is a strong overall performer. With a 'B' rating of 71.8 for overall impact (85th percentile compared to all companies), NextPharma ranks 41st out of 161 industry peers, behind Taiwan High Speed Rail Corp, Evotec, cbdMD and 37 others, and ahead of HOOKIPA Pharma, Equillium, Walvax Biotechnology and 117 others. On top material causes for NextPharma's industry (Pharmaceuticals & Biotech), NextPharma performs well in Access to Affordable Healthcare (95.5 score), Disease Eradication (96.2), Disaster Readiness and Effective Aid (94.8) and 3 other causes where it received an 'A' score and performs poorly in Sustainable Use of Water (38.1 score), Reduced Use of tobacco (31.4) and Equal Pay and Opportunity (36.8).
Impact
Cause PRIVATE.NEXTPHARMA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1946
Employees
2,000
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
PRIVATE.NEXTPHARMA
Description
Operator of a pharmaceutical contract development and manufacturing organization (CDMO) intended for small to mid-size specialty pharmaceutical companies. The company offers a wide range of pharmaceutical services including pharmaceutical development, clinical trials, commercial manufacturing and packaging services, thereby enabling clients to meet their supply chain needs.
Material causes
Ethos considers the following causes material for NextPharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.